Inflammatory Myositis Market: Epidemiology, Therapies, Companies, DelveInsight | CSL Behring, Immunoforge Co. Ltd., Argenx, Janssen, Abcuro, Inc., Horizon Therapeutics, Merck KGaA, Galapagos NV, Priov

Inflammatory myositis market report provides current treatment practices, emerging drug, market size and market share of the individual therapies, current and forecasted 7MM from 2020 to 2034. The report also covers current inflammatory myositis treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Emerging therapies for inflammatory myositis, including Dazukibart (PF-06823859) and others, are anticipated to drive growth in the inflammatory myositis market in the coming years.

DelveInsight has launched a new report on "Inflammatory myositis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Inflammatory myositis, historical and forecasted epidemiology as well as the Inflammatory myositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the inflammatory myositis market report @ https://www.delveinsight.com/report-store/inflammatory-myositis-im-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Inflammatory Myositis Market Report:

*
The inflammatory myositis market across the seven major markets (7MM) was valued at approximately USD 589 million in 2023 and is projected to expand steadily throughout 2024-2034. Within this, the U.S. stood out as the leading contributor, accounting for USD 301 million in 2023, reflecting both strong demand and significant future growth potential.

*
Several innovative therapies, such as PF-06823859 and Brepocitinib, are expected to launch during the forecast period, driving market growth. The overall therapeutics market is anticipated to advance at a robust CAGR of around 11.7% across the 7MM, supported by rising demand for novel treatment options and growing investment in this rare condition.

*
In June 2024, Cabaletta Pharmaceuticals shared encouraging preliminary data from its Phase I/II RESET-Myositis trial in immune-mediated necrotizing myopathy (IMNM). The three-month follow-up results, presented at the EULAR 2024 Congress, underscored the potential of Cabaletta's novel therapeutic strategy. Enrollment in the trial continues, with more comprehensive results expected by late 2024, marking an important milestone in IMNM research.

*
Key industry players-including CSL Behring, Immunoforge, Argenx, Janssen, Abcuro, Horizon Therapeutics, Merck KGaA, Galapagos, Priovant Therapeutics, Roivant, Alexion, Pfizer, Kezar Life Sciences, and others-are actively advancing new candidates to reshape the treatment landscape. Among the most promising emerging therapies are Dazukibart (PF-06823859) and other pipeline agents.

Inflammatory Myositis Overview

Myositis refers to muscle inflammation and is typically associated with a group of inflammatory muscle disorders, such as polymyositis, dermatomyositis, cancer-associated myositis, juvenile dermatomyositis, overlap myositis, and inclusion body myositis (IBM). While myositis denotes inflammation specifically, myopathy is a broader term that covers all muscle diseases or disorders, including but not limited to myositis.

This rare condition can affect not only muscles but also other organs, often leading to a substantial decline in quality of life. The American College of Rheumatology notes that inflammatory myopathies are autoimmune conditions in which the immune system mistakenly targets healthy muscle tissue. Among them, dermatomyositis and polymyositis are the most common forms.

Inflammatory Myositis Market Outlook

Management of inflammatory myositis has advanced over the years, generally relying on a combination of immunosuppressive agents-such as corticosteroids, DMARDs, and biologics-along with physical therapy and supportive interventions. However, there is still an unmet need for more targeted and effective therapies with improved safety profiles. New approaches, including biologics and small-molecule inhibitors, are showing potential to enhance outcomes and influence future market dynamics.

Intravenous immunoglobulin (IVIg) has demonstrated efficacy as a first-line monotherapy in roughly half of patients with idiopathic inflammatory myopathies, often producing benefits within three weeks in those who respond. For patients who do not improve with corticosteroids, other immunosuppressants, or IVIg, intravenous cyclophosphamide may be considered as a fourth-line option, though its significant risks restrict its use to severe, refractory cases. Treatment plans are generally personalized, taking into account disease severity, therapeutic response, and clinical judgment.

Discover how the inflammatory myositis market is rising in the coming years @ https://www.delveinsight.com/sample-request/inflammatory-myositis-im-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Inflammatory Myositis Emerging Drugs

*
Dazukibart (PF-06823859): Pfizer

Scope of the Inflammatory Myositis Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Inflammatory Myositis Companies: CSL Behring, Immunoforge Co. Ltd., Argenx, Janssen, Abcuro, Inc., Horizon Therapeutics, Merck KGaA, Galapagos NV, Priovant Therapeutics, Roivant, Alexion Pharmaceuticals, Pfizer, Kezar Life Sciences, and others

*
Key Inflammatory Myositis Therapies: Dazukibart (PF-06823859), and others

*
Inflammatory myositis Therapeutic Assessment: Inflammatory myositis current marketed and Inflammatory myositis emerging therapies

*
Inflammatory myositis Market Dynamics: Inflammatory myositis market drivers and Inflammatory myositis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Inflammatory myositis Unmet Needs, KOL's views, Analyst's views, Inflammatory myositis Market Access and Reimbursement

To know what's more in our inflammatory myositis report, visit https://www.delveinsight.com/report-store/inflammatory-myositis-im-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Inflammatory Myositis Market Report:

*
Inflammatory myositis market report covers a descriptive overview and comprehensive insight of the Inflammatory myositis Epidemiology and Inflammatory myositis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

*
The Inflammatory myositis market report provides insights into the current and emerging therapies.

*
The inflammatory myositis market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Inflammatory myositis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Inflammatory myositis market.

Got queries? Click here to know more about the inflammatory myositis market Landscape [https://www.delveinsight.com/sample-request/inflammatory-myositis-im-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Inflammatory myositis Patient Share (%) Overview at a Glance

5. Inflammatory myositis Market Overview at a Glance

6. Inflammatory myositis Disease Background and Overview

7. Inflammatory myositis Epidemiology and Patient Population

8. Country-Specific Patient Population of Inflammatory myositis

9. Inflammatory myositis Current Treatment and Medical Practices

10. Unmet Needs

11. Inflammatory myositis Emerging Therapies

12. Inflammatory myositis Market Outlook

13. Country-Wise Inflammatory myositis Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Inflammatory myositis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Inflammatory myositis Market Outlook 2034 [https://www.delveinsight.com/report-store/inflammatory-myositis-im-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Related Reports:

Inflammatory myositis Pipeline Insights, DelveInsight

"Inflammatory myositis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Inflammatory myositis market. A detailed picture of the Inflammatory myositis pipeline landscape is provided, which includes the disease overview and Inflammatory myositis treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=inflammatory-myositis-market-epidemiology-therapies-companies-delveinsight-csl-behring-immunoforge-co-ltd-argenx-janssen-abcuro-inc-horizon-therapeutics-merck-kgaa-galapagos-nv-priov]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.